Zanubrutinib 80 MG for Related Disease
This trial will test whether zanubrutinib is safe and effective in treating patients with a disease related to IgG4.
- Related Disease
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Awards & Highlights
Find a site
Who is running the clinical trial?
Frequently Asked Questions
Is participation in this study currently being sought?
"Affirmative. According to clinicaltrials.gov, the trial is actively searching for subjects since its inception on August 1st 2022 and last update on October 24th 2022. The research requires 10 patients from a single medical centre."
What is the scope of this research project in terms of participants?
"Affirmative. The information accessible on clinicaltrials.gov indicates that this medical inquiry, which was initially uploaded to the website on August 1st 2022, is actively seeking out participants. A total of 10 patients are required from a single site for successful enrollment."
Has the FDA sanctioned Zanubrutinib 80 MG for general consumption?
"Our assessment of Zanubrutinib 80 MG's safety factor has been set to 2, as this Phase 2 trial only provides limited evidence of its security. There is currently no data proving the effectiveness of this medication."
Has this kind of clinical trial ever been conducted before?
"Since its initial research in 2016, Zanubrutinib 80 MG has been approved by Phase 1 and is now under consideration for further clinical trials. MEI Pharma, Inc., initially sponsored the study with 177 participants; since then, 37 live studies have taken place across 324 cities and 32 countries worldwide."
What criteria must a person fulfill in order to be eligible for this clinical research?
"To qualify for this clinical trial, individuals should have been diagnosed with immunoglobulin g4-related disease and must be between 18 to 85 years of age. The team is looking to recruit approximately 10 participants."
What other investigations have taken place concerning Zanubrutinib 80 MG?
"Presently, 8 Phase 3 trials are researching the effects of Zanubrutinib 80 MG. While Palo Alto, California is one location with an active study for this drug, a total of 1104 sites have been deployed for research purposes."
What medical applications does Zanubrutinib 80 MG typically have?
"The medication zanubrutinib 80 MG is often prescribed to those suffering from Waldenstrom macroglobulinemia. Additionally, it has been found to be effective in treating lymphoma and relapsed marginal zone lymphoma after one prior therapy session."
Are people aged 30 and above eligible for this research endeavor?
"This clinical trial has an age range of 18-85 years old, with no exceptions."